Anavex's blarcamesine slowed cognitive decline in phase 2/3 early Alzheimer's trial
Jul. 28, 2024 11:28 PM ET
By: Jonathan Block, SA News Editor
 IvelinRadkov
- Data from a phase 2b/3 trial of Anavex Life Sciences' (NASDAQ: AVXL) blarcamesine (Anavex2-73) showed that the oral drug significantly slowed cognitive decline in early Alzheimer's patients.
- At 48 weeks, the once-daily treatment slowed clinical progression by 38.5% and 34.6%, respectively, at 50 mg and 30 mg doses compared to placebo based on the ADAS-Cog13 measurement, one of the primary endpoints.
- However, a second primary endpoint, did not reach significance by week 48, though was trending positive. Anavex explained this may have happened because "the ADCS-ADL scale is designed for [Alzheimer's] with overt dementia and is less sensitive for early [Alzheimer's]."
- A secondary endpoint, CDR-SB, was significant at both dosage strengths.
- Biomarkers also showed that blarcamesine significantly slowed brain atrophy in the whole brain by 37.6%, total grey matter by 63.5%, and lateral ventricles by 25.1%.
- There were no neuroimaging adverse events reported.
- Anavex plans to submit an application for the candidate to the European Medicines Agency in Q4.
|
